Tags · Clinical

type 2 diabetes

The population with the largest evidence base for these compounds.

65 topics 24 solved Group: Clinical

65 topics · page 2 of 3

Topic	Participants	Replies	Views	Activity
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Solved Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…		2	1.9k	5mo
Hepatic steatosis: what the MASH trial evidence supports — one year on Clinical › Comorbidities MASH / hepatic steatosis obstructive sleep apnoea chronic kidney disease blood pressure Solved On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…		2	4.1k	6mo
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since Compounds › Semaglutide semaglutide SELECT trial type 2 diabetes STEP programme Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…	+6	10	6.1k	8mo
Revisiting: Gallbladder disease risk with rapid weight loss Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease PCOS obstructive sleep apnoea Revisiting: Gallbladder disease risk with rapid weight loss Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…		2	2k	9mo
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide STEP programme SELECT trial randomised trial type 2 diabetes Under review On the subject in the title: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a…	+72	81	1.5k	9mo
Discussing something you have already been doing Clinical › Prescriber conversations prior authorisation type 2 diabetes beginner friendly telehealth Solved Under review On the subject in the title: Discussing something you have already been doing Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…	+10	14	3.4k	10mo
Hypertension improvement and when medication needs revisiting Clinical › Comorbidities type 2 diabetes MASH / hepatic steatosis chronic kidney disease Closed Hypertension improvement and when medication needs revisiting Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+74	79	1.1k	10mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…		4	7.7k	11mo
[2026 update] Cardiovascular risk: reading the outcome trials as a set Clinical › Comorbidities PCOS type 2 diabetes chronic kidney disease blood pressure Posting this under the heading it deserves: Cardiovascular risk: reading the outcome trials as a set Everything below is what sits behind that. Asking about a population rather than about a person. The…	+99	103	32k	11mo
Preparing for an appointment: one page, three questions Clinical › Prescriber conversations prior authorisation type 2 diabetes telehealth Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…	+28	32	57k	11mo
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide SELECT trial type 2 diabetes semaglutide Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+112	119	3.3k	11mo
The C-cell question: rodent findings and their human context Compounds › Semaglutide STEP programme type 2 diabetes effect size Closed Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…	+41	45	24k	12mo
Discussing something you have already been doing — the long version Clinical › Prescriber conversations telehealth prior authorisation beginner friendly type 2 diabetes Solved Discussing something you have already been doing — the long version Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+14	18	58k	12mo
Hepatic steatosis: what the MASH trial evidence supports Clinical › Comorbidities MASH / hepatic steatosis PCOS type 2 diabetes chronic kidney disease Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in…	+77	83	950	13mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
Coming back to: Getting a referral rather than a refusal Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes beginner friendly Solved Posting this under the heading it deserves: Getting a referral rather than a refusal Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…	+69	74	1.7k	13mo
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class Clinical › Comorbidities type 2 diabetes obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The…		2	726	14mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+120	132	2k	14mo
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Compounds › Semaglutide STEP programme randomised trial SELECT trial type 2 diabetes Solved Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Session topic: SURMOUNT-1 ( N Engl J Med ,…	+112	130	2.2k	16mo
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Compounds › Semaglutide STEP programme type 2 diabetes randomised trial effect size Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+125	132	39k	16mo
Gallbladder disease risk with rapid weight loss Clinical › Comorbidities obstructive sleep apnoea type 2 diabetes chronic kidney disease Solved Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…	+56	63	34k	18mo
Coming back to: Preparing for an appointment: one page, three questions Clinical › Prescriber conversations prior authorisation type 2 diabetes telehealth Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…	+139	151	47k	18mo
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide effect size type 2 diabetes randomised trial Solved Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…	+72	77	7.2k	19mo
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial Solved Closed Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…	+94	102	14k	19mo
Second opinions: how to seek one without burning the first Clinical › Prescriber conversations telehealth prior authorisation beginner friendly type 2 diabetes Closed Second opinions: how to seek one without burning the first Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my own care — I…	+1	5	33k	19mo
Asking about a compound your prescriber has not heard of — one year on Clinical › Prescriber conversations beginner friendly type 2 diabetes prior authorisation Solved Under review On the subject in the title: Asking about a compound your prescriber has not heard of — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…	+11	15	3.7k	19mo
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide effect size randomised trial SELECT trial STEP programme Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+1	5	11k	20mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…	+58	62	49k	20mo
How to ask for a dose change without antagonising anyone — what changed since Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes Solved How to ask for a dose change without antagonising anyone — what changed since — that is the question, and I have not found it answered plainly anywhere I have looked. General question, not a request for…	+81	92	10k	20mo
Chronic kidney disease and the FLOW result — a second dataset Clinical › Comorbidities MASH / hepatic steatosis blood pressure type 2 diabetes Chronic kidney disease and the FLOW result — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my own care —…		2	2.3k	20mo